Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ.

Masson Regnault M, Castañeda-Sanabria J, Diep Tran MHT, Beylot-Barry M, Bachelez H, Beneton N, Chosidow O, Dupuy A, Joly P, Jullien D, Mahé E, Richard MA, Viguier M, Tubach F, Sbidian E, Paul C; PsoBioTeq Study Group.

J Eur Acad Dermatol Venereol. 2019 Aug 16. doi: 10.1111/jdv.15878. [Epub ahead of print]

PMID:
31419355
2.

[Infliximab].

Goujon C, Bachelez H; Groupe de recherche sur le psoriasis de la Société française de dermatologie.

Ann Dermatol Venereol. 2019 Jun - Jul;146(6-7):483-486. doi: 10.1016/j.annder.2019.04.013. Epub 2019 Jun 20. French. No abstract available.

PMID:
31230775
3.

Éditorial.

Viguier M, Aubin F, Bachelez H, Beylot-Barry M, Richard MA; Groupe de recherche sur le psoriasis de la Société française de dermatologie.

Ann Dermatol Venereol. 2019 Jun - Jul;146(6-7):423-425. doi: 10.1016/j.annder.2019.04.018. Epub 2019 Jun 20. French. No abstract available.

PMID:
31229352
4.

Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.

Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson AA.

J Am Acad Dermatol. 2019 Jun 5. pii: S0190-9622(19)30899-0. doi: 10.1016/j.jaad.2019.05.095. [Epub ahead of print]

5.

Respiratory virus infection triggers acute psoriasis flares across different clinical subtypes and genetic backgrounds.

Sbidian E, Madrange M, Viguier M, Salmona M, Duchatelet S, Hovnanian A, Smahi A, Le Goff J, Bachelez H.

Br J Dermatol. 2019 Dec;181(6):1304-1306. doi: 10.1111/bjd.18203. Epub 2019 Aug 20. No abstract available.

PMID:
31150103
6.

PAPASH, PsAPASH and PASS autoinflammatory syndromes: phenotypic heterogeneity, common biological signature and response to immunosuppressive regimens.

Gottlieb J, Madrange M, Gardair C, Sbidian E, Frazier A, Wolkenstein P, Hickman G, Schneider P, Baudry C, Claudepierre P, Bertheau P, Richette P, Smahi A, Bachelez H.

Br J Dermatol. 2019 Oct;181(4):866-869. doi: 10.1111/bjd.18003. Epub 2019 Jul 25. No abstract available.

PMID:
30980721
7.

Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis.

Bachelez H, Choon SE, Marrakchi S, Burden AD, Tsai TF, Morita A, Turki H, Hall DB, Shear M, Baum P, Padula SJ, Thoma C.

N Engl J Med. 2019 Mar 7;380(10):981-983. doi: 10.1056/NEJMc1811317. No abstract available.

PMID:
30855749
8.

Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.

Mrowietz U, Bachelez H, Burden AD, Rissler M, Sieder C, Orsenigo R, Chaouche-Teyara K.

J Am Acad Dermatol. 2019 May;80(5):1344-1352. doi: 10.1016/j.jaad.2019.01.066. Epub 2019 Feb 1.

9.

Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.

Strober BE, Gottlieb AB, van de Kerkhof PCM, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R.

Br J Dermatol. 2019 Jan;180(1):67-75. doi: 10.1111/bjd.17149. Epub 2018 Oct 10.

PMID:
30188571
10.

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.

Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H.

Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7.

PMID:
30097359
11.

Trends in hospitalization rates for psoriasis flares since the introduction of biologics: a time series in France between 2005 and 2015.

Polivka L, Oubaya N, Bachelez H, Paul C, Richard MA, Beylot-Barry M, Schmutz JL, Beneton N, Mahé E, Viguier M, Chosidow O, Canoui-Poitrine F, Sbidian E; Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie.

J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1920-1929. doi: 10.1111/jdv.15044. Epub 2018 May 31.

PMID:
29729123
12.

Efficacy of oral sirolimus as salvage therapy in refractory lichen planus associated with immune deficiency.

Mahévas T, Bertinchamp R, Battistella M, Reygagne P, Oksenhendler E, Fieschi C, Bachelez H.

Br J Dermatol. 2018 Sep;179(3):771-773. doi: 10.1111/bjd.16555. Epub 2018 Jun 26. No abstract available.

PMID:
29573394
13.

Image Gallery: Lenalidomide for the treatment of pseudotumoral herpes simplex virus type 2 infection in human immunodeficiency virus infection.

Gottlieb J, Janier M, Battistella M, Bachelez H.

Br J Dermatol. 2018 Jan;178(1):e63. doi: 10.1111/bjd.16041. No abstract available.

PMID:
29357582
14.

Pustular psoriasis and related pustular skin diseases.

Bachelez H.

Br J Dermatol. 2018 Mar;178(3):614-618. doi: 10.1111/bjd.16232. Epub 2018 Jan 15. Review.

PMID:
29333670
15.

Radiation-induced inflammatory dermatosis: Another facet of the immunocompromised cutaneous district.

Haber R, Bachelez H.

JAAD Case Rep. 2017 Nov 10;3(6):572-573. doi: 10.1016/j.jdcr.2017.06.034. eCollection 2017 Nov. No abstract available.

16.

Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long-term results from a randomized controlled, double-blind, 52-week, phase III trial in patients with moderate-to-severe plaque psoriasis.

Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B.

Br J Dermatol. 2017 Dec;177(6):1562-1574. doi: 10.1111/bjd.15857. Epub 2017 Dec 1.

PMID:
28755394
17.

The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis.

Girolomoni G, Strohal R, Puig L, Bachelez H, Barker J, Boehncke WH, Prinz JC.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1616-1626. doi: 10.1111/jdv.14433. Epub 2017 Aug 29. Review.

18.

Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort.

Sbidian E, Giboin C, Bachelez H, Paul C, Beylot-Barry M, Dupuy A, Viguier M, Lacour JP, Schmutz JL, Bravard P, Mahé E, Beneton N, Misery L, Delaporte E, Modiano P, Barbarot S, Regnier E, Jullien D, Richard MA, Joly P, Tubach F, Chosidow O.

J Eur Acad Dermatol Venereol. 2017 Dec;31(12):2046-2054. doi: 10.1111/jdv.14406. Epub 2017 Jul 16.

19.

Mutation in IL36RN impairs the processing and regulatory function of the interleukin-36-receptor antagonist and is associated with DITRA syndrome.

Bal E, Lim AC, Shen M, Douangpanya J, Madrange M, Gazah R, Tauber M, Beghdadi W, Casanova JL, Bourrat E, Bachelez H, Towne JE, Smahi A.

Exp Dermatol. 2019 Oct;28(10):1114-1117. doi: 10.1111/exd.13387. Epub 2017 Oct 26.

PMID:
28603914
20.

Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis.

Papp KA, Bachelez H, Blauvelt A, Winthrop KL, Romiti R, Ohtsuki M, Acharya N, Braun DK, Mallbris L, Zhao F, Xu W, Walls CD, Strober B.

Br J Dermatol. 2017 Dec;177(6):1537-1551. doi: 10.1111/bjd.15723. Epub 2017 Nov 16.

PMID:
28600810
21.

Interleukin 23 inhibitors for psoriasis: not just another number.

Bachelez H.

Lancet. 2017 Jul 15;390(10091):208-210. doi: 10.1016/S0140-6736(17)31474-5. Epub 2017 Jun 6. No abstract available.

PMID:
28596042
22.

Radiation-induced hidradenitis suppurativa: A case report.

Haber R, Gottlieb J, Zagdanski AM, Battistella M, Bachelez H.

JAAD Case Rep. 2017 Apr 14;3(3):182-184. doi: 10.1016/j.jdcr.2017.02.013. eCollection 2017 May. No abstract available.

23.

Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis.

Lopez A, Mariette X, Bachelez H, Belot A, Bonnotte B, Hachulla E, Lahfa M, Lortholary O, Loulergue P, Paul S, Roblin X, Sibilia J, Blum M, Danese S, Bonovas S, Peyrin-Biroulet L.

J Autoimmun. 2017 Jun;80:10-27. doi: 10.1016/j.jaut.2017.03.011. Epub 2017 Apr 2. Review.

PMID:
28381345
24.

A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP).

Reich K, Zschocke I, Bachelez H, de Jong EMGJ, Gisondi P, Puig L, Warren RB, Ortland C, Mrowietz U; PSO-TOP study group.

Br J Dermatol. 2017 Jul;177(1):197-205. doi: 10.1111/bjd.15466. Epub 2017 Jun 6.

PMID:
28301043
25.

Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.

Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Narbutt J, Philipp S, Spelman L, Weglowska J, Zhang N, Strober B.

J Am Acad Dermatol. 2017 Jun;76(6):1093-1102. doi: 10.1016/j.jaad.2016.12.014. Epub 2017 Mar 11.

26.

A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features: results from psoriasis patients in Spain.

Puig L, van de Kerkhof PCM, Reich K, Bachelez H, Barker J, Girolomoni G, Paul C.

J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1176-1182. doi: 10.1111/jdv.14195. Epub 2017 Apr 25.

27.

Prevalence and Risk of Inflammatory Bowel Disease in Patients with Hidradenitis Suppurativa.

Egeberg A, Jemec GBE, Kimball AB, Bachelez H, Gislason GH, Thyssen JP, Mallbris L.

J Invest Dermatol. 2017 May;137(5):1060-1064. doi: 10.1016/j.jid.2016.11.040. Epub 2017 Jan 12.

28.

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.

Reich K, Leonardi C, Langley RG, Warren RB, Bachelez H, Romiti R, Ohtsuki M, Xu W, Acharya N, Solotkin K, Colombel JF, Hardin DS.

J Am Acad Dermatol. 2017 Mar;76(3):441-448.e2. doi: 10.1016/j.jaad.2016.10.027. Epub 2016 Dec 24. Erratum in: J Am Acad Dermatol. 2017 Aug;77(2):390-390.e1.

29.

Lipofilling: A New Therapeutic Option for the Treatment of Lupus Panniculitis-Induced Atrophy.

Polivka L, Revol M, Battistella M, Bachelez H.

Case Rep Dermatol. 2016 Nov 15;8(3):323-326. eCollection 2016 Sep-Dec.

30.

Liver test abnormalities in patients admitted for severe psoriasis: prevalence and associated risk factors.

Finet A, Viguier M, Chazouillères O, Amatore F, Paul C, Richard MA, Chosidow O, Bachelez H, Sbidian E; Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie.

J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1742-1748. doi: 10.1111/jdv.13674. Epub 2016 May 26.

PMID:
27226222
31.

Psoriasis Patients Treated With Biologics and Methotrexate Have a Reduced Rate of Myocardial Infarction: A Collaborative Analysis Using International Cohorts.

Gulliver WP, Young HM, Bachelez H, Randell S, Gulliver S, Al-Mutairi N.

J Cutan Med Surg. 2016 Nov;20(6):550-554. Epub 2016 Jul 8.

PMID:
27402717
32.

Predictors of long-term drug survival for infliximab in psoriasis.

Magis Q, Jullien D, Gaudy-Marqueste C, Baumstark K, Viguier M, Bachelez H, Guibal F, Delaporte E, Karimova E, Montaudié H, Boye T, Aubin F, Beylot-Barry M, Richard MA; “Groupe de Recherche sur le Psoriasis de la Société Française”.

J Eur Acad Dermatol Venereol. 2017 Jan;31(1):96-101. doi: 10.1111/jdv.13747. Epub 2016 Jun 21.

PMID:
27325600
33.

IL36RN Mutations Affect Protein Expression and Function: A Basis for Genotype-Phenotype Correlation in Pustular Diseases.

Tauber M, Bal E, Pei XY, Madrange M, Khelil A, Sahel H, Zenati A, Makrelouf M, Boubridaa K, Chiali A, Smahi N, Otsmane F, Bouajar B, Marrakchi S, Turki H, Bourrat E, Viguier M, Hamel Y, Bachelez H, Smahi A.

J Invest Dermatol. 2016 Sep;136(9):1811-1819. doi: 10.1016/j.jid.2016.04.038. Epub 2016 May 21. Review.

34.

Do Biologics Protect Patients With Psoriasis From Myocardial Infarction? A Retrospective Cohort.

Gulliver WP, Randell S, Gulliver S, Connors S, Bachelez H, MacDonald D, Gladney N, Morrissey A, Fleming P.

J Cutan Med Surg. 2016 Nov;20(6):536-541. Epub 2016 May 10.

PMID:
27207347
35.

Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study.

Egeberg A, Mallbris L, Warren RB, Bachelez H, Gislason GH, Hansen PR, Skov L.

Br J Dermatol. 2016 Sep;175(3):487-92. doi: 10.1111/bjd.14528. Epub 2016 Jun 20.

PMID:
26959083
36.

Chemokine ligand 7 (CCL7) and innate immune cells in psoriasis: beyond redundancy.

Bachelez H.

Exp Dermatol. 2016 Apr;25(4):265-6. doi: 10.1111/exd.12963. No abstract available.

PMID:
26836361
37.

[What's New in Dermatological Therapy?].

Bachelez H.

Ann Dermatol Venereol. 2015 Dec;142 Suppl 3:S49-54. doi: 10.1016/S0151-9638(16)30006-0. Review. French.

PMID:
26792414
38.

Kawasaki disease in adults: Observations in France and literature review.

Fraison JB, Sève P, Dauphin C, Mahr A, Gomard-Mennesson E, Varron L, Pugnet G, Landron C, Roblot P, Oziol E, Chalhoub G, Galempoix JM, Humbert S, Humbert P, Sbidian E, Grange F, Bayrou O, Cathebras P, Morlat P, Epaulard O, Pavese P, Huong du LT, Zoulim A, Stankovic K, Bachelez H, Smail A, Bachmeyer C, Granel B, Serratrice J, Brinchault G, Mekinian A, Costedoat-Chalumeau N, Bourgarit-Durand A, Puéchal X, Guillevin L, Piram M, Koné-Paut I, Fain O; CRI and the French Vasculitis Study Group.

Autoimmun Rev. 2016 Mar;15(3):242-9. doi: 10.1016/j.autrev.2015.11.010. Epub 2015 Nov 26. Review.

39.

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).

Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, Crowley J.

J Am Acad Dermatol. 2016 Jan;74(1):134-42. doi: 10.1016/j.jaad.2015.09.001.

40.

European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.

Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, Arenberger P, Bachelez H, Barker J, Dauden E, de Jong EM, Feist E, Jacobs A, Jobling R, Kemény L, Maccarone M, Mrowietz U, Papp KA, Paul C, Reich K, Rosumeck S, Talme T, Thio HB, van de Kerkhof P, Werner RN, Yawalkar N.

J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2277-94. doi: 10.1111/jdv.13354. Epub 2015 Oct 19. No abstract available.

PMID:
26481193
41.

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.

Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A.

N Engl J Med. 2015 Oct;373(14):1318-28. doi: 10.1056/NEJMoa1503824.

42.

Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013.

Sbidian E, Hotz C, Seneschal J, Maruani A, Amelot F, Aubin F, Paul C, Beylot Barry M, Humbert P, Dupuy A, Caux F, Dupin N, Modiano P, Lepesant P, Ingen-Housz-Oro S, Mahé E, Bachelez H, Chosidow O, Wolkenstein P.

Br J Dermatol. 2016 Mar;174(3):667-70. doi: 10.1111/bjd.14199. Epub 2015 Dec 22. No abstract available.

43.

Interleukin-17 inhibition: a route to psoriasis clearance?

Bachelez H.

Lancet. 2015 Aug 8;386(9993):510-2. doi: 10.1016/S0140-6736(15)60857-1. Epub 2015 Jun 10. No abstract available.

PMID:
26072106
44.

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.

Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, Gupta P, Tan H, Tawadrous M, Valdez H, Wolk R; OPT Compare Investigators.

Lancet. 2015 Aug 8;386(9993):552-61. doi: 10.1016/S0140-6736(14)62113-9. Epub 2015 Jun 4.

PMID:
26051365
45.

Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey.

van de Kerkhof PC, Reich K, Kavanaugh A, Bachelez H, Barker J, Girolomoni G, Langley RG, Paul CF, Puig L, Lebwohl MG.

J Eur Acad Dermatol Venereol. 2015 Oct;29(10):2002-10. doi: 10.1111/jdv.13150. Epub 2015 Apr 16.

46.

Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study.

Reich K, Zschocke I, Bachelez H, de Jong EM, Gisondi P, Puig L, Warren RB, Mrowietz U; TTOP study group.

J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1156-63. doi: 10.1111/jdv.12774. Epub 2014 Oct 26.

47.

Peripheral and local human papillomavirus 16-specific CD8+ T-cell expansions characterize erosive oral lichen planus.

Viguier M, Bachelez H, Poirier B, Kagan J, Battistella M, Aubin F, Touzé A, Carmagnat M, Francès C, Gougeon ML, Fazilleau N.

J Invest Dermatol. 2015 Feb;135(2):418-424. doi: 10.1038/jid.2014.397. Epub 2014 Sep 10.

48.

National survey of psoriasis flares after 2009 monovalent H1N1/seasonal vaccines.

Sbidian E, Eftekahri P, Viguier M, Laroche L, Chosidow O, Gosselin P, Trouche F, Bonnet N, Arfi C, Tubach F, Bachelez H.

Dermatology. 2014;229(2):130-5. doi: 10.1159/000362808. Epub 2014 Aug 23.

PMID:
25171322
49.

Development and psychometric validation of the REFlective evaLuation of psoriasis Efficacy of Treatment and Severity (REFLETS) questionnaire: a common measure of plaque-type psoriasis severity and treatment efficacy for patients and clinicians.

Gilet H, Roborel de Climens A, Arnould B, Bachelez H, Bagot M, Beaulieu P, Joly P, Jullien D, Le Maître M, Ortonne JP, Paul C, Thibout E.

J Eur Acad Dermatol Venereol. 2015 Mar;29(3):498-506. doi: 10.1111/jdv.12601. Epub 2014 Jul 25.

50.

Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study.

Tauber M, Buche S, Reygagne P, Berthelot JM, Aubin F, Ghislain PD, Cohen JD, Coquerelle P, Goujon E, Jullien D, Brixi H, Jeudy G, Guennoc X, Martin A, Brénaut E, Hoppé E, Bertolotti A, Bardin T, Delaporte E, Allez M, Bachelez H, Seneschal J, Viguier M; Groupe de Recherche sur Psoriasis de Société Française de, Dermatologie; Club Rhumatismes et Inflammation (CRI); Groupe d'études thérapeutiques des affections inflammatoires du tube digestif (GETAID).

J Am Acad Dermatol. 2014 Jun;70(6):1146-9. doi: 10.1016/j.jaad.2014.03.005. No abstract available.

PMID:
24831323

Supplemental Content

Loading ...
Support Center